Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
PZ HTL SA

New Company Startup to Launch Genome Information Platform Technology in Japan

By BiotechDaily International staff writers
Posted on 04 Feb 2014
Sony Corp. (Tokyo, Japan) reported that Sony, M3, Inc. (Tokyo, Japan), and Illumina, Inc. (San Diego, CA, USA) have agreed to form a collaboration to launch a genome information platform in Japan.

Sony and M3 will establish a new company with Illumina as a minority investor, by the end of February 2014.

Genome research, which analyzes human genetic data together with medical and other information, has the ability to lead to innovations in identifying the origins of diseases, as well as the development of new pharmaceutical agents and treatment approaches. There is mounting anticipation for new developments in the field of personalized medicine, where drugs or treatments are optimized for the individual patient, and this represents an area where genome research findings are forecast to play an increasingly important role.

The new company’s genome-information platform business will provide a genome analysis service for research institutions and businesses in Japan. It will also aggregate genome data with related information such as medical data to support research in areas where genome data is utilized. The company’s goal will be to contribute to advancements in Japanese customized medicine and healthcare. The extent of its business is expected to extend beyond medical research, to provide a service platform that supports the use of genetic data and medical information for personalized medicine and healthcare services for individual patients.

Tadashi Saito, corporate officer, executive vice president, officer in charge of medical business, Sony Corp., noted, “I’m very excited by the potential of this collaboration to deliver new services and breakthroughs that bring us ever closer to the realization of the personalized medicine and healthcare era. At Sony, we are positioning the medical business as one of our key growth pillars. Together with M3, a Sony Group affiliated company and leader in medical information services, and Illumina, who lead the world in next-generation genome-sequencers, we aim to facilitate genome research that further advances Japanese medical care, and in the future establish a new service platform for the medical industry.”

Itaru Tanimura, representative director of M3, Inc., stated, “The Internet had major impact on our lives. Gene diagnosis and treatment will potentially have the same or even greater influence. The current status of the human genome industry is comparable to the Internet in the early 1990s, when companies such as Google, Amazon, and Facebook had yet to emerge. Going forward, I expect companies and services of this magnitude to also appear in this industry. This three party alliance combines each company’s unique strengths and resources, and together we intend to build a service platform that could not have been realized by others.”

“With the cost of whole genome sequencing falling rapidly, the era of genome-based clinical decisions, personalized medicine, and population health initiatives is on the horizon,” said Jay Flatley, chief executive officer of Illumina. Making use of genomic information for these purposes requires significant data collection and analysis and we are excited to work with Sony and M3 to build a powerful genomic database and lay the groundwork to support population health in Japan.”

P5, Inc. (Tokyo, Japan), which will be the new company’s name, launch is scheduled for end of February 2014, with a capital of JPY 118.75 million.

Related Links:

Sony
M3
Illumina



Channels

Genomics/Proteomics

view channel
Image: Biopsy of small bowel showing celiac disease manifested by blunting of villi, crypt hyperplasia, and lymphocyte infiltration of crypts (Photo courtesy of Wikimedia Commons).

Reduced Elafin Levels Associated with Celiac Disease Bowel Inflammation

Levels of the enzyme elafin, an endogenous serine protease inhibitor, were lower in the small intestinal epithelium of patients with active celiac disease (CD) as compared to similar tissue from control patients.... Read more

Drug Discovery

view channel

Retinoic Acid Prevents Precancerous Breast Cells from Progressing to Full-Blown Cancer

Retinoic acid, a derivative of vitamin A, was found to prevent pre-cancerous breast cells from progressing to full-blown cancer but did not have any effect on breast tumor cells. Investigators at Thomas Jefferson University (Philadelphia, PA, USA) worked with a novel breast cancer model that had been developed by treating... Read more

Biochemistry

view channel

Mitochondrial Cause of Aging Can Be Reversed

Researchers have found a cause of aging in lab animals that can be reversed, possibly providing an avenue for new treatments for age-related diseases including type 2 diabetes, cancer, muscle wasting, and inflammatory diseases. The researchers plan to begin human trials late 2014. The study, which was published December... Read more

Therapeutics

view channel

Cytokine Identified That Causes Mucositis in Cancer Therapy Patients

The action of the cytokine interleukin 1-beta (IL-1beta) has been found to underlie the onset of mucositis, a common, severe side effect of chemotherapy and irradiation of cancer patients. Mucositis occurs as a result of cell death in reaction to chemo- or radiotherapy. The mucosal lining of the mouth becomes thin, may... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.